Whalesbook
📉 The Financial Deep Dive
Cipla's Q3 FY'26 performance revealed a flat year-on-year consolidated revenue of Rs 7,074 crore. This stagnation was primarily attributed to the anticipated decline in generic Revlimid sales. The EBITDA margin, excluding other income, stood at 17.7%, with gross margins at 62.8%, both influenced by lower lenalidomide revenues and the prevailing product mix.
Total expenses saw a 13% YoY increase to Rs 3,187 crore. This rise was a result of planned strategic investments in Research & Development (R&D), manufacturing capabilities, and talent acquisition to support upcoming product launches. R&D expenditure surged by 37.4% YoY to Rs 494 crore, representing 7% of revenue, with a focus on product filings and key development programs.
Profit After Tax (PAT) for the quarter was Rs 676 crore (9.6% of sales). This figure includes a one-time exceptional item of Rs 276 crore related to the implementation of the new labor code.
The "Grill":
A significant point of concern was the disruption in North America. Revenue in the region was $167 million. While the base business excluding Lenalidomide showed double-digit growth, a major setback occurred with Lanreotide. A US FDA inspection at partner Pharmathen's facility resulted in nine 483 observations, leading to a temporary halt in production. Management indicated that resupply is expected in H1 FY'27, and Cipla is evaluating alternate manufacturing sites. This disruption, coupled with lower-than-anticipated Lanreotide performance and the completion of the generic Revlimid billing cycle, led management to revise the FY'26 EBITDA margin guidance to approximately 21%.
🚀 Strategic Analysis & Impact
Cipla's domestic business, branded 'One-India', emerged as a strong growth engine, delivering 10% YoY growth. The branded prescription business also achieved double-digit growth, with key therapy areas such as Respiratory (crossing Rs 5,000 crore in IPM for the first time), Anti-diabetes, and Cardiac demonstrating robust performance. The company expanded its 'INR 100 crore club' by adding four new brands, bringing the total to 30.
Strategic initiatives are bolstering the portfolio. These include a marketing and distribution agreement with Pfizer for four brands in India and a definitive agreement to acquire Inzpera Health Sciences, focusing on pediatric pharmaceutical and wellness products. New product launches during the quarter, such as Afrezza (India's first inhaled rapid-acting insulin) and Yurpeak (tirzepatide therapy), further strengthen the company's offerings.
🚩 Risks & Outlook
The primary risks for Cipla revolve around navigating the decline in Revlimid sales and resolving the Lanreotide production issue in the US. The company is banking on upcoming launches, including four significant respiratory products in the US (such as generic Advair) and three peptide assets slated for FY'27, to offset these revenue declines and sustain long-term growth.
Investors will closely monitor the timeline for Lanreotide resupply and the execution of the US product launch pipeline. Guidance for FY'27 margins will be provided once the annual operating plan is finalized. The company maintained a healthy net cash position of Rs 10,229 crore as of December 31, 2025, providing a stable financial footing.